New hope for malaria patients with G6PD deficiency?
NCT ID NCT07468513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how safe and effective primaquine is for treating vivax malaria in people with intermediate or deficient G6PD enzyme levels. About 100 adults with confirmed malaria and G6PD deficiency will receive either a high daily dose or a weekly dose of primaquine. The goal is to find a treatment that works without causing serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for G6PD DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arba Minch General Hospital
NOT_YET_RECRUITINGArba Minch, Ethiopia
-
Dr Marcus Lacerda
RECRUITINGManaus, Brazil
-
Dr Moses Laman and Dr Brioni Moore
RECRUITINGAlexishafen, Madang Province, Papua New Guinea
-
Papua New Guinea Institute of Medical Research
RECRUITINGPort Moresby, Magang, Papua New Guinea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Can a short drug course end malaria relapses for good?
- Malaria drug combo under scrutiny: could tafenoquine interact?
- 3-Day malaria cure could transform treatment
- New short-course malaria cure could save thousands
- New Short-Course malaria treatment could prevent relapses